Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 4/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.38 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.38 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.38 |
| ▸ | FRK | P42685 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820931 | 0.92 | ELANE (0.36) | MAPK9MAP4K4CSNK1DCDC42BPAMINK1 | |
| SCHEMBL4826214 | 0.86 | RIPK3 (0.37) | ELANEMAPK14MAPK11ROCK2ROCK1 | |
| SCHEMBL4825609 | 0.85 | ORAI1 (0.40) | MAPK9ELANEMAPK14MAPK13MAPK12 | |
| SCHEMBL4824064 | 0.83 | RXRA (0.37) | MAPK9ELANEMAPK14MAPK13MAPK12 | |
| SCHEMBL4817629 | 0.83 | MAPK9 (0.35) | MAPK9MAP4K4CSNK1DCDC42BPAMINK1 | |
| SCHEMBL4817627 | 0.83 | MAPK9 (0.35) | MAPK9MAP4K4CSNK1DCDC42BPAMINK1 | |
| SCHEMBL4825285 | 0.79 | ELANE (0.33) | MAPK9MAP4K4CSNK1DCDC42BPAMINK1 | |
| SCHEMBL4824396 | 0.77 | CPT2 (0.39) | ELANEMAPK14MAPK11ROCK2ROCK1 | |
| SCHEMBL14064562 | 0.73 | MAPK14 (0.38) | MAPK9MAP4K4CSNK1DCDC42BPAMINK1 | |
| SCHEMBL4816447 | 0.72 | NPSR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429594-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429594-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429594-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1656366-A1 | SUBSTITUTED PYRIMDINONE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005019202-A1 | SUBSTITUTED PYRIMDINONE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043301-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043301-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | MAPK9 1787/4885MAP4K4 1286/4885CSNK1D 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.